PHASE-I STUDY OF AZIRIDINYLBENZOQUINONE (NSC 182986)

  • 1 January 1981
    • journal article
    • research article
    • Vol. 4  (4) , 459-463
Abstract
A phase I clinical study of aziridinylbenzoquinone (AZQ) was conducted in 33 patients with various types of advanced solid tumors to evaluate its toxicity and efficacy. The initial dose of 0.5 mg/m2 per day .times. 5 days repeated at 3-wk intervals was progressively increased to a maximum dose of 12.0 mg/m2 per day. Thrombocytopenia was the dose-limiting toxic efect; it was delayed, cumulative and occurred more often in patients with extensive prior chemotherapy and radiotherapy. Anemia was common and severe at higher doses; nausea and vomiting were observed only in some patients and usually were mild. Objective tumor regressions were observed in 3 of 17 patients who received biologically active doses of AZQ, i.e., 6 mg/m2 per day or higher. Minor responses were seen in 2 of 3 patients with malignant melanoma and in 1 patient with adenocarcinoma of unknown primary. The recommended starting dose of AZQ for good-risk patients is 8.0 mg/m2 per day .times. 5 days for phase II studies.

This publication has 1 reference indexed in Scilit: